Can GLP-1 Medications Slow Aging? What the Research Actually Shows

Medically reviewed by Mace Scott, M.D., Medical Director at Chronos Body Health & Wellness. Last reviewed: 10/19/26.

Losing weight is one thing. Slowing the aging process is a much bigger claim.

So when headlines suggest that medications like semaglutide and tirzepatide could influence biological aging, they deserve a closer look.

As a physician, I find this research interesting because it asks a question that matters well beyond the scale: Could treating metabolic disease help people stay healthier as they get older?

The early findings are promising. But understanding what researchers measured—and what they haven’t established yet—is essential.

Can GLP-1 medications slow biological aging?

Early research suggests semaglutide and tirzepatide may improve certain molecular markers associated with biological aging. However, these findings do not prove that the medications reverse aging or extend human lifespan.

An October 2026 article in MIT Technology Review highlighted aging research from Novo Nordisk and Eli Lilly. Researchers reported changes in “aging clocks,” tools that estimate biological age using patterns in blood proteins or chemical markers on DNA. The size of the changes varied depending on the measurement used.

That distinction matters. A change in an aging score is an intriguing signal. Whether it translates into additional healthy years requires further research.

What is biological age?

Chronological age is straightforward: it’s how many birthdays you’ve had.

Biological age is an estimate of aging-related changes in your body. Researchers use different tools to study those changes, including:

• Epigenetic clocks, which analyze chemical markings on DNA.
• Proteomic clocks, which analyze patterns in protein levels.

These tools examine different aspects of aging, so they can produce different answers. Think of them as research instruments that offer clues about health and disease risk, rather than a definitive reading of how “old” your body is.

What did the semaglutide research find?

A 2026 research abstract examined semaglutide using blood-protein data from participants in the SELECT, STEP 1, and STEP 2 clinical trials.

Researchers found reductions in biological age estimates from clocks combining organ-specific proteins. However, a separate category of clocks using non-organ-specific proteins did not show a treatment effect.

That is an important part of the story. The findings suggest semaglutide can influence particular aging-related protein patterns, but they do not show that every measure of aging improves. This report was a conference abstract, which provides less detail than a full research paper.

A separate peer-reviewed study published in Nature Communications examined semaglutide and DNA-based aging markers in 84 adults with HIV-associated excess abdominal fat.

Over 32 weeks, semaglutide improved several aging-clock measurements compared with placebo. One measure suggested an approximately 9% slower pace of biological aging.

However, this was an exploratory analysis conducted after the original trial was designed. It involved a small, specific patient population, and the results cannot automatically be applied to everyone taking semaglutide.

What about tirzepatide?

Tirzepatide, which acts on both GIP and GLP-1 receptors, has also been studied for its effects on aging markers.

According to the 2026 Aging Research and Drug Discovery conference recap, researchers analyzed blood samples from participants over age 50 in a tirzepatide subgroup of SURMOUNT-5. Several DNA-based aging measures improved over 72 weeks.

There is a significant limitation: this aging analysis examined the tirzepatide group alone. Without a comparison group in that analysis, it is harder to determine how much of the change was caused by treatment.

These results help identify questions worth studying. They do not establish tirzepatide as an anti-aging treatment.

Does a younger aging-clock result mean you will live longer?

No. These studies have not established that conclusion.

Several questions remain:

• Do improvements in aging markers predict fewer illnesses or better physical function?
• Do the changes persist over time?
• How much is related to weight loss versus other medication effects?
• Would people without obesity or metabolic disease receive similar benefits?

When I evaluate research like this, I want to know what eventually changes for the patient. Can they remain active? Maintain independence? Avoid a serious medical event?

Those are the outcomes that make an aging-related discovery clinically meaningful.

We already have evidence of benefits beyond weight loss

While aging-clock research is still developing, some benefits beyond weight reduction are better established.

In the SELECT trial, 17,604 adults with overweight or obesity and existing cardiovascular disease—but without diabetes—received semaglutide or placebo.

Major cardiovascular events occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over approximately 40 months. That represents a 20% relative reduction, or a 1.5 percentage-point absolute reduction, in that specific population.

That finding carries a different level of clinical weight because researchers measured actual cardiovascular events.

It also illustrates why medical weight management deserves a broader conversation than how quickly someone can lose weight.

What this means for your treatment plan

My takeaway is that aging research gives us another reason to study these medications carefully. It does not give us a reason to prescribe them to everyone seeking longevity.

Treatment decisions should still begin with your medical history, health risks, goals, and whether a medication is appropriate for you.

Potential benefits also need to be weighed against side effects and contraindications. Semaglutide can cause gastrointestinal symptoms and carries warnings involving conditions such as pancreatitis and gallbladder disease. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.

For patients receiving treatment, I would keep the focus practical: Are you tolerating it? Are you eating adequately? How are your energy, strength, and daily function? What does your follow-up evaluation tell us?

A compelling headline should start a conversation with your provider. Your individual health should guide the decisions that follow.

Frequently asked questions

A broader approach to medical weight management

At Chronos Body Health & Wellness in Metairie, we believe weight management deserves medical attention that looks beyond a number on the scale.

If you’re considering semaglutide or tirzepatide, our team can help you understand your options and develop a plan based on your health and goals.

Schedule a medical weight loss consultation with us today.

This article is for educational purposes and does not replace personalized medical advice.